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Vascular function of the peripheral circulation in patients with While the importance of proteinuria as a prognostic
nephrosis. marker for progression of renal disease is established,
Background. Nephrotic syndrome is associated with abnor- its significance as a risk factor for cardiovascular diseasemal lipoprotein metabolism and increased risk of coronary heart
is less widely appreciated, particularly in nondiabeticdisease. Endothelial dysfunction, an early phase of atherogenesis
populations [1]. Nephrotic syndrome is characterized bythat manifests as impaired flow-mediated dilation (FMD) of the
peripheral circulation, may link these associations. heavy proteinuria 3.5 g/day, hypoalbuminemia, hyper-
Methods. We examined endothelial function of the brachial coagulability, edema, and dyslipoproteinemia [2]. An in-
artery and forearm resistance arteries in 15 patients with ne-
creased incidence of coronary disease also has been re-phrosis (NP), 15 patients with primary hyperlipidemia (HL)
ported in nephrotic patients, but the basis for this increasealone, and 15 normolipidemic, nonproteinuric subjects (NC)
matched for age, sex, and weight. The NP and HL groups had remain unclear [3].
similar serum cholesterol and triglyceride concentrations. Post- Plasma lipid abnormalities are universal in nephrosis
ischemic FMD (endothelium-dependent) and glyceryl trini- (NP) [2, 4]. Mixed hyperlipidemia (HL) frequently re-trate-mediated dilation (GTNMD; endothelium-independent)
sults from abnormal apolipoprotein B-100 (apoB) trans-of the brachial artery were studied using ultrasonography and
port [5]. Qualitative changes in high-density lipoproteincomputerized edge detection software. Postischemic forearm
blood flow was also measured using plethysmography. (HDL) and elevations in plasma lipoprotein (a) [Lp(a)]
Results. Postischemic FMD of the brachial artery was signifi- may also occur [5]. Dyslipoproteinemia [6], hypoalbumi-
cantly lower in the NP and HL groups compared with NC nemia [7], and hyperfibrinogenemia [8], recognized car-group (mean  SE): NP 4.91  0.8%, HL 4.53  0.6%, NC
diovascular risk factors in the community, may collectively8.45 0.5% (P 0.001). There were no significant differences
among the groups in baseline diameter and GTNMD of the account for the increased incidence of cardiovascular
brachial artery, nor in maximal forearm blood flow and flow disease in NP in the absence of renal failure [3]. Their
debt repayment of the forearm microcirculation. Significant relative contributions, as well as the role of less conven-
differences in FMD among the groups were principally related
tional risk factors, such as insulin resistance and low-to differences in serum low-density lipoprotein cholesterol.
density lipoprotein (LDL) particle size, are unclear, how-Conclusions. Patients with NP have abnormal endothelium-
dependent but preserved endothelium-independent dilation of ever. Whether treating dyslipoproteinemia in NP is of
the brachial artery following an ischemic stimulus. Postischemic clinical benefit remains to be established [4].
forearm microcirculatory function is unimpaired. Dyslipopro- Endothelial dysfunction is an early phase of athero-teinemia is probably the principal cause of endothelial dysfunc-
sclerosis resulting from perturbations in the physiologytion of conduit arteries in patients with NP and the basis for
their increased risk of cardiovascular disease. of several vasoactive molecules, principally nitric oxide
(NO) [9, 10]. Endothelial function of peripheral conduit
arteries may be measured following an ischemic stimulus
using high-resolution ultrasonography [11]. Microcircu-
latory endothelial function may also be assessed noninva-
sively using venous-occlusion, strain-gauge plethysmog-Key words: proteinuria, lipids, endothelial function, dyslipoproteine-
mia, cardiovascular disease, ischemia, atherogenesis. raphy [12]. Endothelial dysfunction of the brachial artery
correlates with abnormal vasomotor responses of the cor-Received for publication August 11, 2000
onary circulation [13], predicts coronary events [14, 15],and in revised form January 18, 2001
Accepted for publication January 22, 2001 and is associated with conventional cardiac risk factors
[16, 17]. Abnormal forearm hyperemic responses may also 2001 by the International Society of Nephrology
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reflect generalized microcirculatory dysfunction [18]. Clinical and laboratory methods
Forearm microcirculatory responses to intra-arterially All patients had a medical examination and a 12-lead
administered 5-hydroxy-tryptamine (5-HT), an NO ago- electrocardiogram (EKG). Resting blood pressure (BP)
nist, have been previously shown to be abnormal in NP and heart rate were measured using a Dinamap (Critikon
[19]. Whether endothelial dysfunction extends to other Ltd., Tampa, FL, USA). Urinary protein excretion was
vessels and the relative effects of dyslipidemia, hypoal- assessed in the nephrotic patients and in the other groups
buminemia, and hyperfibrinogenemia on endothelial by 24-hour urine collection and early morning urinary
dysfunction remains to be determined. protein/creatinine ratio, respectively. BMI (kg/m2) was
We therefore examined endothelial function noninva- derived from height and weight measurements. Venous
sively in two peripheral arterial systems in nephrotic blood was obtained in the semirecumbent position after
a 12-hour fast and with minimal venous stasis. Serumpatients and in patients with primary HL. Using a case-
cholesterol and TG were measured by enzymatic meth-control design, we aimed principally to assess the role
ods. HDL cholesterol was estimated after precipitationof dyslipoproteinemia in the pathogenesis of arterial dis-
of apoB-containing lipoproteins with heparin/manganese.ease in NP, as well as the contributory effects of other
Serum LDL cholesterol was calculated by the Friedewaldvariables, including plasma albumin, fibrinogen, and
equation, but was assayed directly with a commercialhomocysteine levels.
assay (LDL-C; Boehringer Mannheim GmBH, Mann-
heim, Germany) on a Hitachi 917 Biochemical Autoana-
METHODS lyzer (Hitachi Ltd., Tokyo, Japan) in patients with TG
4.5 mmol/L. Plasma glucose was assayed by the hexoki-Subjects and study design
nase method, and serum and urinary creatinines wereFifteen patients with NP, 15 with primary HL and 15
measured by modified Jaffe´ reaction. Glomerular filtra-healthy, normolipidemic, nonproteinuric (NC) subjects
tion rate was calculated using the Cockcroft and Gaultwere recruited from renal clinics, lipid clinics, and the
formula. Serum albumin and urinary protein were mea-community, respectively. The groups were matched for
sured on a Hitachi 917 autoanalyzer. Lp(a) and apoBage, sex, and body mass index (BMI). The NP and HL
were assayed by immunonephelometric methods. LDLgroups were selected to have similar serum total choles-
particle diameter was determined using nondenaturingterol, triglyceride (TG), and LDL cholesterol levels. In
gel electrophoresis [20]. Homocysteine was measured bythis study, NP referred to a primary glomerulopathy
a fluorescence polarization immunoassay (Axis Biochem-resulting in a classic nephrotic syndrome or an associated
icals ASA, Oslo, Norway) and fibrinogen by the Claussresidual nephrotic range proteinuria. Primary HL was
method. The interassay coefficients of variation (CVs)defined as HL in the absence of a recognized precipitat-
were all 6%.
ing cause, with or without classic clinical stigmata and a
family history of coronary disease. Subjects with cardio- Brachial artery ultrasonography
vascular disease, diabetes, hypothyroidism, liver disease, During the ultrasound procedure, subjects rested su-
alcoholism, postural hypotension, intercurrent illnesses, pine in a quiet, temperature-controlled (24C) room. The
and significant psychiatric disorders were excluded. Pa- left arm was immobilized in a foam cast and supported
tients were studied off lipid-lowering drugs (for at least comfortably in extension and supination. A high-resolu-
4 weeks) and aspirin. Patients were not excluded for tion 12 mHz linear array transducer connected to an
taking angiotensin-converting enzyme (ACE) inhibitors, Acuson Aspen System (Acuson Pty Ltd., Mountain
angiotensin II receptor antagonists, diuretics, or a stable View, CA, USA) was employed for the majority of ultra-
dose of other antihypertensive drugs, since these treat- sounds, but a few early scans were carried out using a
ments constitute best clinical practice and patients were 7.5 mHz linear-array vascular transducer connected to
studied in an outpatient setting. We carried out a cross- a Toshiba SSA-270A ultrasound system (Toshiba Corp.,
sectional comparison of vascular function of the periph- Tokyo, Japan). Continuous EKG monitoring was per-
eral circulation among the nephrotic, hyperlipidemic, formed in all studies. The transducer was placed 5 to 10
and normolipidemic groups. Vascular function studies cm proximal to the antecubital crease and fixed in posi-
of the brachial artery and forearm microcirculation were tion by a stereotactic clamp. After good images were
carried out in the morning after a 12-hour fast from food obtained, the edge-to-lumen interface was further opti-
and beverages and after resting in the supine position mized using depth and gain controls, and an edge en-
for at least 15 minutes. Smoking was not allowed on the hancement function. Images were recorded on s-VHS
day of the test. The study received approval from the videotape (Sony MQSE 180) for retrospective analysis.
Royal Perth Hospital Ethics Committee, and all volun- A pneumatic tourniquet was placed around the left fore-
arm, and after recording the baseline images for twoteers gave informed written consent.
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minutes, the cuff was rapidly inflated to 200 mm Hg for selection of the steepest gradient of each flow curve,
five minutes. Forearm-reactive hyperemia was induced assuming the change in flow to be directly proportional
by sudden release of the cuff. Images were recorded to the change in voltage with respect to time; the in-
continuously from 30 seconds before to 4 minutes after traobserver CV was 5%, but the within-subject CV
cuff release. A second resting scan was obtained at least was of the order of 25% [21]. BP was measured before
10 minutes after cuff deflation to ensure that the brachial and after the procedure using a semiautomatic sphygmo-
artery diameter returned to the basal level. Four hundred manometer (Dinamap; Critikon Ltd., Tampa, FL, USA).
micrograms of glyceryl trinitrate (GTN) were adminis- A sphygmomanometer cuff was placed over the left up-
tered sublingually by spray, and the images were re- per arm and inflated to 40 mm Hg above systolic BP to
corded continuously for a further five minutes. induce forearm ischemia for four minutes. After releas-
Analysis of postischemic flow and GTN-mediated dila- ing the cuff, blood flow was measured for four minutes.
tion of the brachial artery was carried out using semiauto- The initial peak after the ischemic period was defined
mated edge detection software recently developed and as the hyperemic response or maximal blood flow, ex-
validated within our department. During the s-VHS play- pressed as mL/100 mL of forearm/min. Flow debt repay-
back into a digital frame grabber, digital images were ment was defined as the area under the blood flow curve
displayed on a personal computer. A rectangular region (mL/100 mL of forearm), equivalent to the excess blood
of interest (ROI) was drawn around the most representa- flow during hyperemia, and was derived from the hyper-
tive section of the artery. A second ROI was selected emic blood flow curve using nonlinear regression analysis
around the EKG tracings and a third ROI for calibration [21]. Forearm vascular resistance (FVR) was also mea-
of the diameter measurements. The computerized edge- sured using the formula: mean arterial pressure (MAP)/
detection and wall-tracking software system then auto-
maximal FABF. Forearm length (l) and forearm circum-matically determined the brachial artery diameter at the
ference (c) were measured in order to calculate the fore-end diastole, each frame corresponding to up to 300 indi-
arm volume: (c2  l)/4.vidual diameter measurements. A third order polyno-
mial function was applied to the curve of serial, end- Statistical methods
diastolic diameter measurements, to derive maximal
Group comparisons were carried out using analysis offlow-mediated dilation (FMD) and glyceryl trinitrate-
variance with Bonferroni adjustments. Group differencesmediated dilation (GTNMD) of the brachial artery. Re-
in postischemic FMD were adjusted for other variablessponses were calculated as the percentage of change in
by general linear modeling. Skewed variables were logbrachial artery diameter from baseline. All analyses were
transformed to normalize their distribution, and thoseperformed by two experienced observers. In our hands,
that remained skewed were analyzed using nonparamet-the analytical CV of the computerized technique is of
ric techniques. Associations were examined using univar-the order of 12% compared with at least 35% using more
iate and mutivariate regression methods. Variables thatconventional visual estimations employing calipers. The
were significant at the 10% level in univariate analysis orCV for within-subject measurements (N  30) in FMD
were considered, a priori, to influence vascular functionis of the order of 20%.
were employed in the multiple regression models. Statis-
Forearm microcirculation tical significance was defined at the 5% level.
Subjects were studied after 10 minutes of rest in a
supine position in a quiet, temperature-controlled (24C) RESULTS
room. Measurement of forearm blood flow (FABF) was
Table 1 shows the glomerular histology, disease dura-carried out using venous occlusion plethysmography with
tion, and renal function of the patients with NP. Twomercury-in-Silastic strain gauges connected to a plethys-
patients did not have a biopsy-proven diagnosis at themograph (Hokanson EC4; Hokanson, Bellevue, WA,
time of the study. The median (range) duration of glo-USA) connected to MacLab/4e (ADI Instruments, Syd-
merular disease was six (1 to 156) months. The mean ney, Australia). The strain gauges were calibrated elec-
SD 24-hour urinary protein excretion was in the ne-tronically and placed 5 cm below the antecubital crease
phrotic range at 6.3  4.6 g/24 h and serum albuminof the left arm. To isolate the FABF from the hand, a
decreased at 26.1  7.2 g/L. Serum creatinine and glo-wrist cuff was inflated to 200 mm Hg during measure-
merular filtration rates were 99.3  31.9 mol/L andment periods. The upper arm (or collecting) cuff was
76.8  33.4 mL/min, respectively. Five patients wereinflated rapidly to 40 mm Hg to impede venous outflow
being treated with ACE inhibitors, either enalapril, quin-but allow arterial inflow, causing swelling of the forearm
april, perindopril, trandolapril, or lisinopril, and twoand stretch of the strain gauge. The cuffs were set to
were taking an angiotensin II receptor antagonist (irbe-inflate for 10 seconds and deflate for 7 seconds.
sartan and losartan). Two patients had just commencedForearm blood flow was obtained by recording the mean
oral corticosteroid treatment. Eight patients had clini-of three representative curves and was expressed as mL/
100 mL of forearm/min. It was calculated in MacLab by cally detectable peripheral edema.
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Table 1. Histological features, renal function and angiotensin-converting enzyme (ACE) inhibitor treatment of the patients with nephrosis
Disease Urinary Serum Serum Calculated
duration protein albumin creatinine GFR ACE
Patient no. Glomerular histology months g/24 h g/L lmol/L mL/min inhibitor
1 Focal and segmental glomerulonephritis 48 1.4 40 137 56.9 yes
2 Membranous glomerulonephritis 5 6.4 26 89 67.7 yes
3 Mesangiocapillary glomerulonephritis type 1 156 1.0 32 67 69.2 no
4 Minimal change disease 2 2.2 26 56 136.6 no
5 No biopsy 2 15 26 154 36.4 yes
6 Minimal change disease 4 5.5 19 66 92.4 no
7 IgA glomerulonephritis 84 4.8 33 136 46.2 no
8 Mesangioproliferative glomerulonephritis 6 6.9 26 70 76.5 no
9 Membranous glomerulonephritis 12 1.4 33 90 90.5 yes
10 Focal and segmental glomerulonephritis 24 3.3 28 135 28.5 yes
11 No biopsy 1 7.4 15 83 73.9 no
12 Minimal change disease 7 7.5 20 102 65.3 no
13 Minimal change disease 1 16.2 20 118 70.8 no
14 Membranous glomerulonephritis 54 5.5 32 66 153.8 no
15 Minimal change disease 1 9.3 15 120 87.4 no
Mean 27.1 6.3 26.1 99.3 76.8
SD 43.4 4.6 7.2 31.9 33.4
Table 2. Demographic and clinical characteristics of the nephrotic (NP), hyperlipidemic (HL), and normolipidemic (NC) groups
NP HL NC
Number 15 15 15
Sex male/female 10/5 11/4 8/7
Age years 45.5 (3.7) 41.8 (3.8) 47.6 (3.5)
Weight kg 76.8 (4.2) 78.8 (3.8) 73.7 (3.1)
BMI kg/m2 27.3 (1.6) 26.1 (0.9) 25.3 (1.0)
SBP mm Hg 123 (3.4)b 114 (2.3) 112 (3.1)
DBP mm Hg 75 (2.6) 69 (2.2) 67 (1.8)
Pulse pressure mm Hg 49 (2.4) 45 (1.5) 45 (2.3)
Heart rate bpm 65 (2.8) 64 (2.1) 58 (2.3)
Forearm volume mL 1536 (96.6) 1627 (101.0) 1413 (71.0)
Urinary protein:creatinine ratio mg/mmol 541.6 (88.6)a 3.8 (1.0) 3.3 (0.5)
Smoker 2 0 0
ACE inhibitor 5 0 0
Mean (SE) shown. Abbreviations are: NP, nephrotic patients; HL, hyperlipidemic controls; NC, normolipidemic controls; BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure; ACE, angiotensin-converting enzyme.
a P  0.0001 vs. other groups
b P  0.05 vs. NC
The demographic and clinical characteristics of the subjects had either familial hypercholesterolemia, familial
combined HL, or common hypercholesterolemia.patients with NP and of the HL and normolipidemic
(NC) control groups are shown in Table 2. Age, weight, The serum lipid, lipoprotein, glucose, insulin, creati-
nine, and albumin concentrations of the three groupsBMI, and the proportion of males to females were not
statistically different among the groups. Systolic BP was are shown in Table 3. Cholesterol, TG, LDL cholesterol,
and apoB were significantly higher in the NP and HLonly significantly higher in the NP compared with the
NC group (P  0.03), but was not in the hypertensive subjects compared with the NC controls. Lp(a) was high-
est in the NP group, but differed only significantly fromrange. There were no significant differences in diastolic
BP, pulse pressure, heart rate, or forearm volume among the NC controls. Serum HDL cholesterol concentration
and LDL particle size were similar among the groups.the groups. Urinary protein excretion was grossly higher
in the NP compared with the HL and NC subjects, with There was a trend to significantly higher glucose in both
the NP and HL groups compared with the NC groupno significant differences between the latter groups. Two
of the nephrotic patients were current smokers, and all (P 0.05), but none of the subjects had diabetes mellitus.
The nephrotic patients had a markedly lower serum albu-of the HL and NC subjects were nonsmokers. None of
the nephrotic patients gave a history of familial HL or min concentration compared with the controls (P 
0.001). Serum creatinine, calculated glomerular filtrationpremature cardiovascular disease, nor were known to be
hyperlipidemic prior to developing renal disease. The HL rate, and plasma homocysteine did not differ significantly
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Table 3. Blood lipids, lipoproteins, and other biochemical measurements in the nephrotic (NP), hyperlipidemic (HL),
and normolipidemic (NC) groups
ANOVA
NP HL NC P value
Cholesterol mmol/L 10.4 (0.8)a 8.6 (0.5)a 4.7 (0.2) 0.001
Triglyceride mmol/L 3.6 (0.9)a 2.0 (0.3)a 0.8 (0.1) 0.001
LDL chol mmol/L 6.9 (0.7)a 6.3 (0.5)a 2.8 (0.2) 0.001
HDL chol mmol/L 1.6 (0.1) 1.3 (0.1) 1.5 (0.1) 0.406
ApoB-100 g/L 1.9 (0.2)a 1.5 (0.1)a 0.8 (0.05) 0.001
Lp(a) g/L 0.6 (0.2)c 0.2 (0.03) 0.1 (0.04) 0.029
LDL particle size nm 25.8 (0.2) 26.0 (0.1) 26.2 (0.06) 0.082
Glucose mmol/L 5.2 (0.2) 5.2 (0.1) 4.8 (0.01) 0.050
Albumin g/L 26 (1.9)ab 42 (0.6) 44 (0.8) 0.001
Creatinine lmol/L 99.3 (8.2) 87.1 (3.5) 82.9 (3.2) 0.105
Homocysteine lmol/L 10.8 (1.0) 8.7 (0.6) 9.2 (0.7) 0.159
Fibrinogen g/L 4.2 (0.5)bc 1.9 (0.1) 2.5 (0.2) 0.001
Abbreviations are: LDL chol, low-density lipoprotein cholesterol; HDL chol, high-density lipoprotein cholesterol; ApoB-100, apolipoprotein B-100; Lp(a),
lipoprotein (a). Mean (SE) are shown.
a P  0.001 vs. NC
b P  0.001 vs. HL
c P  0.05 vs. NC
among the groups. Plasma fibrinogen was markedly ele- (r  	0.45, P  0.002), LDL cholesterol (r  	0.53,
P  0.001), apoB (r  	0.43, P  0.004), and baselinevated (P  0.001) in the nephrotic patients compared
with the two control groups. brachial artery diameter (r  	0.51, P  0.001), but
not with any other variables. After adjusting for otherThere were no significant differences in prestimulatory
brachial artery diameter among the three groups [NP variables, only LDL cholesterol remained significantly
associated (P  0.05) with FMD of the brachial artery.mean 3.56 0.12 mm (SE), HL 3.80 0.18, NC 3.29
0.14]. The results of the poststimulatory changes in bra- Consistent with the study design, the association between
chial artery diameter are shown in Figure 1. Postischemic FMD and LDL cholesterol lost significance after ad-
FMD of the brachial artery was significantly lower in justing for group assignment. In the nephrotic group
both the NP (P  0.002) and HL (P  0.001) groups alone, postischemic FMD was not significantly correlated
compared with NC group, with no significant difference with other variables, including serum lipid, lipoprotein,
between the former two groups: NP 4.91  0.8% albumin and creatinine concentrations, age, BP, or use
(mean  SE), HL 4.53  0.6%, NC 8.45  0.5% (P  of ACE inhibitor. There was also no significant differ-
0.001; Fig. 1A). However, there were no significant dif- ence in FMD between the seven patients taking ACE
ferences in GTNMD of the brachial artery among the inhibitors or angiotensin II receptor antagonists and
three groups (Fig. 1B). The findings shown in Figure 1 those not taking these agents (4.8  1.3 vs. 5.0  1.0%,
were also obtained after omitting the two smokers in P  0.937).
the NP group. In a general linear model, group assign-
ment was not a significant predictor of FMD response
DISCUSSIONafter adjusting for the serum LDL cholesterol and base-
Our study provides new evidence that patients withline brachial artery diameter. In similar models, including
nephrotic proteinuria and preserved renal function haveother variables, for example, age, gender, Lp(a), HDL or
endothelial dysfunction of the brachial artery that is com-Tg, fibrinogen, glucose, albumin or BP, group assignment
parable to that in patients with primary HL. This abnor-remained a significant predictor (P  0.05) of FMD.
mality was principally related to increased plasma con-There were no significant differences among the groups
centrations of LDL cholesterol and did not extend toin terms of basal FABF, maximal blood flow, flow debt
the forearm microcirculation.repayment, or minimum vascular resistance of the fore-
While several studies have shown endothelial dysfunc-arm microcirculation (Table 4). However, mean arterial
tion in established renal failure [22–24], few have focusedpressure at the time of the forearm test was significantly
on vascular function in patients with proteinuria alone.higher in the patients with NP compared with the NC
Stroes et al showed impaired forearm microcirculatorygroup alone (P  0.05; mean  SE): NP 90.8  2.7
responses to 5-HT in a small number of proteinuric pa-mm Hg, HL 83.9  1.9, NC 81.9  2.2.
After pooling data from the three groups, postischemic tients [19]. They concluded that this was a consequence
of a specific defect in endothelial release of NO, since theFMD of the brachial artery was significantly correlated
with serum total cholesterol (r  	0.52, P  0.001), TG abnormality was not seen with infusion of sodium nitro-
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Table 4. Vascular function of the forearm microcirculation in the
nephrotic (NP), hyperlipidemic (HL), and
normolipidemic (NC) groups
NP HL NC
Basal FABF mL/100 mL/min 1.98 (0.2) 2.13 (0.1) 2.31 (0.2)
Maximal blood flow
mL/100 mL/min 18.07 (2.3) 21.25 (2.6) 19.26 (2.2)
Flow debt mL/100 mL 4.84 (1.31) 5.23 (0.7) 4.89 (0.6)
Forearm vascular resistance
mm Hg/mL/100 mL/min 6.74 (1.2) 5.27 (1.1) 5.70 (1.2)
Mean (SE) are shown. FABF is forearm blood flow.
emic blood flow [26, 27]. Given the differences in the
degree of dependence on NO of the hyperemic responses
measured by brachial ultrasonography and by forearm
plethysmography, our results suggest that NP chiefly af-
fects endothelium-dependent as opposed to endothelium-
independent vascular function.
Extensive data suggest that oxidized LDL impairs the
expression of endothelial NO synthase (eNOS), as well as
the synthesis and release of NO in response to stimuli,
such as increased hemodynamic flow [17, 28, 29]. Native
LDL similarly may cause endothelial dysfunction by de-
creasing the activity of NO via a pro-oxidant effect [30],
as well as by increasing the plasma concentration of asym-
metric dimethylarginine (ADMA) [31], an inhibitor of
eNOS. It is likely but unproven that impaired brachial
artery function in both the nephrotic and hyperlipidemic
subjects was due to the effect of the accumulation of LDL
on the endothelial synthesis and release of NO and possi-
bly on the oxidative catabolism of NO to peroxynitrite.
The latter is not supported, however, by the normal vascu-
Fig. 1. Postischemic flow-mediated dilation (FMD; A) and glyceryl lar responses to GTN. Other data refute involvement oftrinitrate-mediated dilatation (GTNMD; B) of the brachial artery in
both decreased basal release of NO and a functional de-the nephrotic (NP), hyperlipidemic (HL), and normolipidemic (NC)
groups. Horizontal bars are mean values, and P values refer to one- ficiency in l-arginine, the substrate for NO synthesis,
way analysis of variance. NS is not statistically significant. and instead suggest a role for lysophosphatidylcholine-
modified LDL [19]. Nonreversal of endothelial dysfunc-
tion with l-arginine in nephrotic patients may exclude a
specific role of hypercholesterolemia, at least in the fore-prusside nor with coadministration of 5-HT and NG-mono-
methyl-l-arginine (L-NMMA), a specific inhibitor of NO arm microcirculation [19]. However, not all studies have
demonstrated that microcirculatory endothelial dysfunc-synthase. We extend this report by using a larger sample
size and hyperlipidemic controls and by noninvasively tion in hypercholesterolemia is reversible by l-arginine
[32]. We cannot fully exclude that increased plasma con-testing vascular function in two peripheral arterial sys-
tems. Our suggestion that impaired vascular function in centrations of remnant lipoproteins [33] and of Lp(a)
[34] contributed to the impaired brachial artery vasodila-NP relates principally to elevated plasma concentrations
of LDL cholesterol concurs with other findings [16]. tion in our patients. Small-dense LDL and low HDL are
also associated with hypertriglyceridemia and endothe-Postischemic flow-mediated dilation of brachial and
other conduit arteries results predominantly from the en- lial dysfunction [35, 36], but did not differ significantly
among our study groups.dothelial release of NO [12, 17, 25]. Hyperemic responses
of forearm resistance arteries are mediated, however, by Since brachial artery vasodilation results from the ab-
luminal release of endothelial NO, we consider it unlikelyseveral agonists, including prostaglandins, adenosine, and
NO, as well as by myogenic and neural mechanisms that low serum albumin was responsible for endothelial
dysfunction in our nephrotic patients, acknowledging[26, 27]. Previous experiments involving coinfusion of
L-NMMA have shown that in normal subjects, NO only that albumin is a reservoir for NO in plasma and is a
vasorelaxant [37, 38]. Furthermore, brachial artery FMDcontributes to less than 25% of forearm-reactive hyper-
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was similar in our patients with normal and low serum tive and qualitative defects in endothelial function of the
peripheral circulation. The causal role of elevated plasmaalbumin concentrations. Mild hyperglycemia could also
have contributed to endothelial dysfunction in the ne- LDL cholesterol in endothelial dysfunction in NP re-
quires confirmation in an intervention study.phrotic and hyperlipidemic groups, but this effect was
more likely in the forearm microcirculation [39, 40]. Hy-
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